JP2022510505A5 - - Google Patents

Info

Publication number
JP2022510505A5
JP2022510505A5 JP2021547963A JP2021547963A JP2022510505A5 JP 2022510505 A5 JP2022510505 A5 JP 2022510505A5 JP 2021547963 A JP2021547963 A JP 2021547963A JP 2021547963 A JP2021547963 A JP 2021547963A JP 2022510505 A5 JP2022510505 A5 JP 2022510505A5
Authority
JP
Japan
Prior art keywords
ring
pharmaceutically acceptable
acceptable salt
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510505A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001175 external-priority patent/WO2020089687A2/en
Publication of JP2022510505A publication Critical patent/JP2022510505A/ja
Publication of JP2022510505A5 publication Critical patent/JP2022510505A5/ja
Priority to JP2024174912A priority Critical patent/JP2025020130A/ja
Pending legal-status Critical Current

Links

JP2021547963A 2018-10-31 2019-10-30 縮合複素環ベンゾジアゼピン誘導体及びその使用 Pending JP2022510505A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024174912A JP2025020130A (ja) 2018-10-31 2024-10-04 縮合複素環ベンゾジアゼピン誘導体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753605P 2018-10-31 2018-10-31
US62/753,605 2018-10-31
PCT/IB2019/001175 WO2020089687A2 (en) 2018-10-31 2019-10-30 Fused heterocyclic benzodiazepine derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024174912A Division JP2025020130A (ja) 2018-10-31 2024-10-04 縮合複素環ベンゾジアゼピン誘導体及びその使用

Publications (2)

Publication Number Publication Date
JP2022510505A JP2022510505A (ja) 2022-01-26
JP2022510505A5 true JP2022510505A5 (cg-RX-API-DMAC7.html) 2022-11-08

Family

ID=70463931

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547963A Pending JP2022510505A (ja) 2018-10-31 2019-10-30 縮合複素環ベンゾジアゼピン誘導体及びその使用
JP2024174912A Pending JP2025020130A (ja) 2018-10-31 2024-10-04 縮合複素環ベンゾジアゼピン誘導体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024174912A Pending JP2025020130A (ja) 2018-10-31 2024-10-04 縮合複素環ベンゾジアゼピン誘導体及びその使用

Country Status (11)

Country Link
US (1) US12274898B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873912B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022510505A (cg-RX-API-DMAC7.html)
CN (2) CN113929707A (cg-RX-API-DMAC7.html)
AU (1) AU2019370859B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008354A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118026A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191180A1 (cg-RX-API-DMAC7.html)
IL (1) IL282530B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021004918A (cg-RX-API-DMAC7.html)
WO (1) WO2020089687A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102710962B1 (ko) 2017-07-04 2024-09-27 주식회사 인투셀 절단성 링커를 포함하는 화합물 및 이들의 용도
CN112166115A (zh) 2018-05-29 2021-01-01 尹图赛利有限公司 新型苯二氮杂*衍生物及其用途
EP3873912B1 (en) 2018-10-31 2026-03-25 Intocell, Inc. Fused heterocyclic benzodiazepine derivatives and uses thereof
MX2021008095A (es) * 2019-01-03 2021-08-05 Intocell Inc Compuestos que comprenden un enlazador escindible y sus usos.
EP3906063A4 (en) 2019-01-03 2023-03-01 Intocell, Inc. COMPOUNDS COMPRISING A CLEAVABLE LINKER AND THEIR USES
CN114728075B (zh) * 2019-12-02 2025-10-03 尹图赛利有限公司 与分子缀合相关的组合物和方法
CN115942978A (zh) * 2020-06-26 2023-04-07 尹图赛利有限公司 包含抗b7-h3抗体的抗体-药物缀合物

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5843937A (en) 1996-05-23 1998-12-01 Panorama Research, Inc. DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
CA3014224C (en) 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
DE102010064282B4 (de) 2010-12-28 2012-09-06 GLOBALFOUNDRIES Dresden Module One Ltd. Liability Company & Co. KG Transistor mit eingebetteten sigma-förmigen sequenziell hergestellten Halbleiterlegierungen
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
HK1211208A1 (zh) 2012-08-22 2016-05-20 Immunogen, Inc. 細胞毒性苯並二氮呯衍生物
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
CN107231804B (zh) * 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
TW201632531A (zh) * 2015-01-14 2016-09-16 必治妥美雅史谷比公司 苯二氮呯二聚物,其結合物及製造與使用方法
KR20170128256A (ko) 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. Cd48 항체 및 이의 접합체
US9504694B2 (en) * 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
EP3458050A1 (en) 2016-05-20 2019-03-27 Abbvie Stemcentrx LLC Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition
WO2018053552A2 (en) * 2016-09-19 2018-03-22 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
CN110049780A (zh) 2016-10-10 2019-07-23 塞勒兰特治疗公司 异喹啉并苯并二氮杂卓(iqb)-1(氯甲基)-2,3-二氢-1h-苯并[e]吲哚(cbi)二聚体
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体
WO2018195243A1 (en) * 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
KR102710962B1 (ko) 2017-07-04 2024-09-27 주식회사 인투셀 절단성 링커를 포함하는 화합물 및 이들의 용도
GB201714115D0 (en) 2017-09-04 2017-10-18 Femtogenix Ltd Cytotoxic agents
CN112166115A (zh) 2018-05-29 2021-01-01 尹图赛利有限公司 新型苯二氮杂*衍生物及其用途
EP3873912B1 (en) 2018-10-31 2026-03-25 Intocell, Inc. Fused heterocyclic benzodiazepine derivatives and uses thereof
KR102503143B1 (ko) 2019-03-06 2023-02-24 주식회사 레고켐 바이오사이언스 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
CN115942978A (zh) 2020-06-26 2023-04-07 尹图赛利有限公司 包含抗b7-h3抗体的抗体-药物缀合物
KR102586030B1 (ko) 2021-12-03 2023-10-11 주식회사 로킷헬스케어 바이오 물질 동결 경화 방식이 적용된 바이오 프린터 및 그 동결 경화 방법
WO2023118961A1 (en) 2021-12-21 2023-06-29 Intocell, Inc. Antibody drug conjugates comprising toxins with polar groups and uses thereof

Similar Documents

Publication Publication Date Title
JP2021525730A5 (cg-RX-API-DMAC7.html)
KR101988005B1 (ko) 개선된 연결을 갖는 아마톡신-접합체
JP2023055973A (ja) 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
JP2025510629A (ja) カンプトテシンコンジュゲート
CN105530942B (zh) 一种包含大环内酯类非对映体的药物组合物、其制备方法和用途
CN114053426B (zh) 一种双药链接组装单元及双药靶向接头-药物偶联物
JP2020512270A5 (cg-RX-API-DMAC7.html)
KR20230079085A (ko) 항종양 화합물 및 그의 제조 방법 및 용도
AU644802B2 (en) Substituted imidazoles
US20200392108A1 (en) Antibody-drug conjugates and related compounds, compositions and methods
KR20210053871A (ko) 캄프토테신 접합체
JP2022549510A5 (cg-RX-API-DMAC7.html)
MXPA05010471A (es) Profarmacos inhibidores de quinasa pi-3.
JP2014528466A5 (cg-RX-API-DMAC7.html)
JP2006523237A5 (cg-RX-API-DMAC7.html)
JP2020506951A5 (cg-RX-API-DMAC7.html)
JP2012516896A5 (cg-RX-API-DMAC7.html)
JP2018511628A5 (cg-RX-API-DMAC7.html)
JP2018516243A5 (cg-RX-API-DMAC7.html)
JP2024521919A5 (cg-RX-API-DMAC7.html)
JP2022512401A5 (cg-RX-API-DMAC7.html)
JP2016516010A (ja) アマトキシン誘導体
JP2022515884A5 (cg-RX-API-DMAC7.html)
CA3012960A1 (en) Tubulysin analogs and methods for their preparation
JP2019508391A5 (cg-RX-API-DMAC7.html)